Logo

BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer

Share this

BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer

Shots:

  • The P-III CheckMate -9LA study involve assessing of Opdivo (360mg q3w) + Yervoy (1mg/kg q6w) combined with CT (two cycles) vs CT as monothx. (up to four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with advanced NSCLC regardless of PD-L1 expression and histology
  • The P-III CheckMate -9LA study resulted in meeting 1EPs of superior overall survival (OS) at a pre-specified interim analysis. 2EPs includes PFS- ORR and efficacy measures according to biomarker
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while the Opdivo and Yervoy dual regimen was the first Immuno-Oncology combination to receive approval for metastatic melanoma and is approved in 50+ countries including the US & EU

Click here to­ read full press release/ article 

Ref: BMS | Image: BMS 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions